Legalized in 2016, medical cannabis in Australia is just starting to get underway. The country is at a tipping point, thanks to the growing number of patients, an increasing number of registered presc...
April is Parkinson’s Disease Awareness Month. According to the Parkinson’s Foundation, there are more than one million people living with the disease in the US alone. In addition, reports ...
Lysergic acid diethylamide (LSD) has a long and colorful history in psychiatric research. Over the last 75 years, waves of excitement have been quickly tempered by waves of fear. For decades, controve...
According to the results in Google Trends, worldwide searches for cannabis stocks have fallen dramatically in recent years. With investors practically falling over themselves before and during the ini...
Cannabis for glaucoma first made headlines in the 1970s, when there weren’t a lot of appealing medications on the market. At the time, cannabis promised fewer side effects and an impressive ability ...
The atmosphere is different in Israel. The country’s approach to supply, production, and research on medical cannabis is in sharp contrast to that in the United States. For starters, Israe...
In early 2022, Canada became one of the first developed countries to allow patients limited access to psychedelic therapies. Only available for emergency purposes and specifically for patients experie...
The American legal landscape is changing. There are now just 14 states that still prohibit medical and adult-use cannabis. But, heading into 2022, many of these lingering holdouts have legislation or ...
Psychedelic drugs are experiencing a rapid evolution. In only a few short years, formerly demonized substances like LSD and magic mushrooms have become the darlings of medical researchers. Psil...
Transdermal medicines have several immediate benefits. First, a transdermal patch applied to the surface of the skin provides sustained drug delivery over a prolonged period. It also helps reduce the ...
According to numbers released by the National Institute of Mental Health, approximately seven percent of American adults experienced social anxiety in the last year. This prevalence increases slightly...
Walk into a cannabis retailer these days, and it’s more than likely you’ll encounter a series of new cannabinoids. Instead of just delta-9 (tetrahydrocannabinol, THC), other intoxicating, ...
The buzz around ketamine for depression is at a fever pitch. The New York Times has called it “The Ketamine Cure,” while the Washington Post labeled it the “Biggest Advance For Depre...
Cannabis contains more than a hundred known cannabinoids, each stimulating a subtly different effect within the human body. But, what happens when a cannabinoid enters the body? Where does it go, what...
The evidence supporting medical cannabis for the side effects of cancer treatments is well established. But what about cannabis for treating cancer itself? Much of the research remains in very pr...
Riding the wave of medical cannabis legislation and research, new (or perhaps renewed) attention is being directed at the potential of psychedelic medicines. Psilocybin, lysergic acid diethylamide (LS...
On the third anniversary of medical cannabis legalization in the UK, there are a total of three patients with a prescription through the public system. Many more patients receive cannabis-derived medi...
Colombia has become the darling of legalized cannabis in Latin America (LATAM). With medical cannabis, scientific study, and export legal in South America’s northernmost country, expectations fo...
Approximately four percent of American adults live with attention deficit hyperactivity disorder (ADHD). Typically diagnosed in childhood between the ages of three to six, this neurological disorder p...
The goal of palliative care is to alleviate the suffering of patients with a chronic diagnosis. End-of-life care is not a curative approach but one focused on relief and quality of life. Palliative tr...
In the ever-evolving world of global medical cannabis policy, Latin American countries don’t always make the headlines. Yet, Brazil, one of the region’s largest markets, is quietly, if inc...
Despite hundreds of thousands of patients legally using medical cannabis to treat a broad spectrum of conditions, it remains frustratingly difficult to dose. There are no official guidelines or dosing...
Should there be limits on THC? As a wave of adult-use cannabis legislation sweeps across the country, many states are proposing strict potency limits, hoping to keep consumers safe. While most r...
Since the 1970s, researchers have been investigating motivation in relation to cannabis use. Interestingly, while the stereotype about the unmotivated stoner persists to this day, most research finds ...
Since the early days of the HIV/AIDS epidemic, LGBTQ activists have fought for patient access to medical cannabis. In the 1980s and ‘90s, this community pushed for legal access, established compassi...
Jersey and Guernsey, two Crown Dependencies located in the United Kingdom’s Channel Islands region, are self-governed. Each with its own government and independent judicial system, they’ve...
In the world of cannabis research, the landscape is about to dramatically change for US-based scientists. Researchers will soon have access to flower and other cannabis products that actually represen...
Considering the NFL reported the highest rate of injury ever in 2020, it only makes sense that they are thinking outside the box for pain management. In a shocking turn of events, the league announced...
In December 2018, New Zealand legalized medical cannabis. In 2019, they created the Medical Cannabis Agency, and what it has called the Medical Cannabis Scheme. In a twist the country voted down recre...
By some estimates, upwards of 90 percent of patients with an advanced cancer diagnosis suffer from chronic pain. Cancer-related pain can stem from the progression of cancer itself or from the various ...
It has long been challenging for researchers to put medical cannabis through well-controlled clinical trials. For starters, the strict scheduling of cannabis at the federal level has limited the scope...
On May,4th 2021, RYAH Group went live on the Canadian Stock Exchange (CSE) under the ticker symbol RYAH. RYAH’s journey started a year and a half ago and required navigating several unpredictabl...
Since 2018, RYAH Data has recorded more than 14,500 sessions from patients treating nausea with medical cannabis. Yet, as far back as 1975, researchers have known about the effects cannabis has had on...
Once a world leader when it comes to medical cannabis, Canada’s federally regulated program has stagnated since 2015. This stagnation has, in part, been a repercussion of the introduction of recreat...
For millennia, humans have added plants into topical preparations designed for medicinal purposes. Alongside popular herbal remedies like aloe vera, arnica, and witch hazel, cannabis is earning renewe...
As of March 31st, 2021, New York is the 17th state (including a district) to have legalized recreational marijuana. After several false starts on the path towards full legalization, America’s th...
Ask people why they have turned to medical cannabis and a majority will indicate stress and anxiety. Since 2018, patients using the RYAH Data ecosystem have logged more than 48,000 sessions for stress...
As political winds shift and the world enters into an age appreciative of medical cannabis, it’s critical to understand the effects this plant has on the human brain. Undeniably, cannabis impact...
In 2019, we published a piece exploring the correlation between increased access to medical cannabis and a decrease in opioid use. Two years is a long time when it comes to medical cannabis research, ...
In the RYAH Data ecosystem, approximately 42 percent of patients prefer sativa and sativa-dominant cultivars, while 44.2 percent prefer indica and indica-dominant strains. Under a scientific lens, do ...
Women’s health, a topic traditionally excluded from scientific research, is slowly getting more recognition. Menopause is one such condition getting renewed attention, including through the lens...
Between January 1, 2018, and November 1, 2020, there have been more than 9,000 sessions of patients consuming medical cannabis for obsessive-compulsive disorder (OCD) within the RYAH Data ecosystem. T...
For decades, the misunderstood relationship between cannabis and schizophrenia has sowed fear among regulators, healthcare providers, and law enforcement. Opposition to legalization has often come wra...
The world is in the midst of an unprecedented global pandemic. Governments, research centers, and international health organizations are throwing everything they have at finding a solution to the newl...
First it won over millennials. Then came the Baby Boomers. Now medical cannabis is piquing the interest of patients over the age of 65. Despite initial hesitations during the first wave of legalizatio...
The UK may have legalized medical cannabis in 2018, but that doesn’t mean patients can access it. According to a recent report in The Guardian, just two patients are receiving medical cannabis t...
The endocannabinoid theory of disease began with the discovery of the endocannabinoid system. Unlike the central nervous system, the respiratory system, and other essential systems which have been inv...
The European cannabis market is a much different beast than what has evolved across the pond in North America. If North America is about wild market predictions, high-risk investments, and murky regul...
Nearly a decade ago, a team of researchers hailing from the University of São Paulo, Brazil, worked with a group of 24 participants diagnosed with social anxiety disorder. Divided into groups, the pa...
The French are standing on the precipice of significant policy change. In the last year, France has made progressively confident legislative steps towards a medical cannabis program. In January 2020, ...
Cannabis for pediatric care? What initially may sound like a shocking and perhaps controversial subject is already a reality. In 2020, cannabis and the plant’s derivatives are well into preclini...
Whether national sports leagues are ready for the transition or not, cannabis is a growing component of sports medicine and athletic wellness. Players from across the sports spectrum are advocating fo...
On Monday, February 24, 2020, RYAH Medtech announced a brand new technology set to revolutionize the delivery of plant-based (and non-plant-based) medicines. The RYAH Smart Transdermal Patch is the fi...
Sleep is consistently one of the primary reasons why people turn to cannabis-based therapies. Within RYAH Data it’s the fifth most common ailment treated, no matter the demographic. This prefere...
Medicinal and recreational advocates have long loved the mildly sedative, sleep-promoting qualities of cannabis, but what does the research actually show us? Stoner stereotypes aside, cannabis has a l...
Based on the early reporting, there is a growing consensus that 2020 may not be the year the US government passes any significant cannabis legislation. Other, more attention-grabbing national headline...
In America, medical cannabis is an ever-changing legal landscape. With any major federal change likely a few years off, state policymakers have been busy creating unique, state-based programs to meet ...
Change is coming to the medical cannabis landscape in the US, but it’s not as rapid as many would hope. Bipartisan political blockades seem to be getting in the way of meaningful cannabis ref...
Undeniably, medical cannabis is going through a rapid period of transition. Heading into 2020, what new revelations can be expected? Only a few short years ago, it remained an ‘alternative’...
Since its establishment almost two decades ago, Movember has become a global phenomenon. Alongside testicular cancer and mental health, prostate cancer awareness is one of the core focus areas of the ...
A year and a half after the Food and Drug Administration (FDA) changed its opinion on cannabis-based pharmaceuticals, the European Commission has followed suit. In September, 2019 GW Pharmaceuticals a...
With Movember 2020 in full swing, there is once again a focus on men’s health issues: prostate cancer, testicular cancer, and mental health. Movember exists to shine a light on conditions that o...
The cannabis industry seems to hold many assumptions about the female patient. The stereotype of the female patient is clear after a single Google: they stick with CBD-rich and low potency strains, th...
In 2017, Germany began the careful rollout of a national medical cannabis program. Since then, there has been a noticeable shift in European policy towards the medicinal use of the plant. Subtle regul...
The session reports within RYAH Data indicate patients are frequently using cannabis for mental health issues. Anxiety, stress, and depression are the top conditions treated, as reported by every sing...
In July, the Arthritis Foundation discovered an astonishing number of American survey respondents—79 percent—reported they were either currently or formerly relying on cannabidiol (CBD), or were c...
By now, the statistics about the opioid crisis in North America are well known. Many of us are familiar with the impacts of opioid prescription use and abuse. After more than a decade of headlines, th...
The statistics on chronic pain make it clear just how prevalent a problem it is in the US. Anywhere from 11 to 40 percent of American adults experience chronic pain, “with considerable populatio...
September is Pain Awareness Month, a month dedicated to highlighting the experience of chronic pain and its effects on individuals, families, and the global community. Pain is just as common amo...
Millennials are a generation with a growing love for cannabis. Not only are they the most likely demographic to have tried cannabis, but they also have the most favorable opinions on it. It should com...
Dilemmas of Dosing: Part III of a III Part Series Read Part I: Cannabis Research Fails to Accurately Capture Real Life Medical Cannabis Use Read Part II: The Challenges of Popular Methods of Consumpt...
Track and trace systems are, by now, integral aspects of regulatory oversight within the cannabis ecosystem. The various government-mandated systems fit snuggly into place between third-party testing ...
Dilemmas of Dosing: Part II of a III Part Series Read Part I: Cannabis Research Fails to Accurately Capture Real Life Medical Cannabis Use In this RYAH exclusive series, “The Dilemmas of Dosing,...
The strange evolution of the cannabis industry traveled down a road unique in modern medicine. To this day, medical cannabis is available in dozens of countries and the majority of US states. But in m...
National headlines over the past year have frequently highlighted the growing demand for cannabis among Baby Boomers. A generation who grew up during the peak of the American War on Drugs, and who may...
With the patchwork of policies, timelines, and legislation covering the medical cannabis sector in the US, the training of the budtender varies from one location to the next. The customer service pr...
RYAH JULY REPORT A CURIOUS GENERATION: BABY BOOMERS & CANNABIS RYAH JULY REPORT A CURIOUS GENERATION: BABY BOOMERS & CANNABIS MEDICAL CANNABIS & COGNITIVE EFFECTS...
The Dilemmas of Dosing: Part I of III Part Series In this RYAH exclusive series, “The Dilemmas of Dosing,” we will explore other challenges facing both patients and providers as they try t...
Smoking remains one of the most popular methods of consumption for medical cannabis patients. Despite the lingering popularity, smoking is still controversial. The reputation of the tobacco industry h...
